2月24日，省政府召开"人工智能+医疗健康"推进工作专题会议，深入学习贯彻习近平总书记关于人 工智能发展和健康中国建设的重要论述，全面落实党中央、国务院关于"人工智能+"决策部署，按照省 委工作要求，促进人工智能在医疗卫生领域的规范应用，创新开展预防、诊疗、康复、健康管理等全链 条智能服务，更好满足人民群众日益增长的健康服务需求。省长刘小涛主持会议并讲话。 刘小涛指出，医疗健康是民生福祉的重要组成部分，是人工智能应用最广泛、需求最迫切的领域之 一，要科学把握产业发展趋势和医疗痛点堵点，将人工智能技术融入医疗健康服务与治理的全领域全过 程，积极推进"人工智能+医疗健康"发展。要聚力建设高质量数据集，推动"三医"协同和跨部门数据共 享，实现居民全生命周期医疗健康数据的高效汇集。着力打造安全可靠的医疗健康数据公共平台，推进 可信数据空间建设，积极探索数据赋能运营和成果转化。加快垂类大模型研发，形成和落地一批临床专 病专科垂类大模型和智能体应用、基层诊疗智能辅助和患者就诊智能服务应用。加强算力中心建设，推 进算力基础设施建设和本地化部署，提供统一、高效、开放的人工智能算力服务。突出场景驱动，聚焦 创新药研发、高端医疗 ...

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, anticipating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of AI infrastructure development in healthcare [1] - The company has embedded itself in national-level AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions and alleviating the burden on healthcare personnel through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates solid technical capabilities, ranking among the top tier in accuracy and traceability during scenario tests conducted by Citigroup, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing its unique advantage to the large-scale, high-quality data sourced from top hospitals [2] - The company's government and hospital-facing business segments show more predictable profitability, benefiting directly from increased AI budgets in hospitals and national project tenders [2] - Citigroup has adjusted its financial forecasts for Yidu Tech, expecting revenue from its big data platform to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, indicating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates strong technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing unique advantages to the quality and authority of its data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Financial forecasts have been adjusted, with expectations for the big data platform revenue to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech and raises its target price to HKD 11, anticipating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product portfolio to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions and alleviating the burden on healthcare personnel through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates solid technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's strong foundation in medical data governance and knowledge construction, attributing its unique advantage to the large scale and quality of data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Citigroup has adjusted its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in big data platform revenue for fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

当AI走进社区诊室，看病的方式正在改变。去年10月以来，苏州试运行基层AI全科医生服务应用，通过智能辅诊和数字家医系统，让居民在家门口获得 更精准、更便捷的医疗服务，一场从基层开始的智慧医疗升级已经展开。 2月5日上午，在苏州相城元和街道社区卫生服务中心的诊室里，患者丁爱华把随身带来的血压记录本递给医生。过去几天，她因为头晕反复发作有些焦 虑，一度担心老毛病加重。这一次，她原本做好了跑大医院排队检查的准备。 丁爱华在元和街道社区卫生服务中心问诊 几分钟问诊下来，医生结合电脑端实时弹出的AI提示，逐条核对她的血压波动、用药情况和伴随症状，很快理清了原因与调整方案。丁爱华松了一口 气："在家门口就解决了，还比想象中细致。" 扬子晚报/紫牛新闻记者了解到，这样的变化，来自正在苏州部分基层医疗机构试点区验证的AI全科医生系统。技术悄悄嵌入社区门诊日常流程，让许多 居民第一次直观感受到：社区医院的诊疗能力，正在变得更加可靠。 丁爱华的就诊流程，也是当前基层门诊的一个缩影。进入诊室前，她已通过系统提前填写基本病情信息。接诊时，医生打开AI全科医生界面，系统自动 同步既往健康记录，并根据主诉生成问诊提示。整个过程更像一次有 ...

对于现代服务业而言，发展的核心命题始终是融合与价值。我们不仅要关注技术本身的先进性，更要洞 察其如何与传统服务流程深度融合，如何提升服务能级、改善用户体验、创造新的商业价值。在医疗健 康这一领域，这意味着要推动人工智能从赋能工具走向核心组件，深刻融入预防、诊断、治疗、康复及 健康管理的全链条，最终构建起以人为中心、智能高效、可及可负担的现代健康服务体系。 上海现代服务业联合会始终致力于构建开放协同的产业生态，推动服务业向高端化、智能化、绿色化方 向升级。我们乐见于此图谱的发布，能够为政、产、学、研、医、投各方搭建一个交流与合作的平台， 促进理念共识与行动协同。期待与各界有识之士携手，共同把握"人工智能+"的时代机遇，不仅推动AI 与医疗健康的深度融合，更以此为示范，探索现代服务业高质量发展的未来路径，为服务国家战略与人 民美好生活贡献行业智慧与力量。 当今时代，服务业的内涵与外延正被技术革命深刻重塑。以人工智能为代表的新兴技术，不仅是提升效 率的工具，更是驱动模式创新、价值链重构与产业生态融合的核心力量。在此背景下，"人工智能+现 代服务业"的深度融合，已成为培育新质生产力、构筑未来发展优势的战略支点。 上海 ...

Core Insights - OpenAI and Anthropic have launched health features for general users and products for the healthcare industry, marking their entry into the healthcare sector [1] - ChatGPT has over 800 million users, with 25% submitting health-related queries weekly, and over 40 million daily consultations on health issues [1][7] - The Chinese government has released guidelines to promote AI in healthcare, leading to the emergence of AI health assistants [1][15] Group 1: Global Trends in Conversational AI Health Assistants - Conversational AI health assistants are becoming a new highlight in the domestic AI + healthcare landscape [2][3] - International users prefer general AI assistants for medical consultations, while specialized AI assistants are helping reduce the workload of doctors in Europe and the US [2][5][9] Group 2: Driving Factors and Challenges - Changes in interaction habits and advancements in AI capabilities are driving a new wave of healthcare service upgrades [15][16] - The competition in AI applications is intensifying, with healthcare being viewed as a new growth area [15][18] - Despite the promising outlook, conversational AI health assistants face numerous challenges [21] Group 3: Development Strategies for AI Health Assistants - There is a need to enhance data openness and innovation support to drive industry innovation through AI health assistants [27] - Industry self-regulation is essential, along with increased safety measures for AI health assistants [30][31] Group 4: Future Prospects - The potential for conversational AI health assistants to become a new entry point for traffic is increasing [33] - The demand for health management is rising, especially among the aging population and health-conscious younger generations [35][36] Group 5: Market Dynamics and Business Models - The pressure for commercial monetization is leading to strategic choices, with the healthcare market seen as a significant opportunity [19][23] - Various potential business models for AI health assistants are still in early exploration stages [23] Group 6: Regulatory and Ethical Considerations - The regulatory framework for AI health assistants is still unclear, necessitating adjustments to promote development [24] - There is a call for industry self-discipline to ensure sustainable AI transformation in healthcare [31][32]

Core Insights - Jiangsu Province is focusing on the integration of artificial intelligence and healthcare to address pain points in medical insurance services through technological innovation [1][3] - The "Shanhai" large model developed by Yunzhisheng serves as the foundational technology for intelligent medical insurance processing, auditing, and decision-making [1][3] - The project is the first provincial-level vertical medical insurance large model initiative in China, with successful bids for both the large model and intelligent application projects [1][3] Company Developments - Yunzhisheng, a pioneer in the commercialization of general artificial intelligence (AGI), has positioned its "Shanhai" large model as a world-class capability in the medical field [3][5] - The company plans to launch the "Shanhai·ZhiYi Model 5.0" in December 2025, marking a significant advancement from "intelligent tools" to "clinical collaborators" [3][5] - The "Smart Medical Product Matrix" based on this model has been deployed in nearly 400 hospitals nationwide, with over 700 additional hospitals in the testing phase [3][5] Strategic Initiatives - Yunzhisheng is advancing three core projects: a foundational medical insurance large model, a high-quality medical knowledge base, and an intelligent management platform for application lifecycle management [5][8] - The company is also establishing the "Yunzhisheng Academy OPC Community" to focus on cutting-edge areas like AIGC, providing a dual-driven model of "technology empowerment + scene cultivation" [5][7] - Jiangsu Province aims to enhance collaboration between government and enterprises, optimize service guarantees, and foster an ecosystem for the digital health industry [8]

中国发展网讯 江苏省政府近日召开新闻发布会，正式介绍《江苏省"人工智能+"行动方案》推进情况。发布会由 省政府办公厅新闻协调处处长韩小平主持，江苏省发展改革委副主任蔡剑峰、省卫生健康委副主任、省中医药管 理局局长朱岷、省数据局王万军、省工业和信息化厅二级巡视员王丹中、省教育厅二级巡视员吴仁林、省科技厅 二级巡视员万发苗一同出席并回答记者提问。 朱岷重点介绍了"人工智能+医疗健康"领域的进展。她表示，江苏始终坚持围绕百姓健康需求，利用医疗健康数据 与场景融合，提升服务效率、改善就医体验，目前已取得三方面积极成效。 一是建成全国领先的"数字基座"。江苏已打造全省统一的卫生健康云，每日千万级健康数据交互，覆盖1.56亿人 口，累计数据量1557亿条，存储规模达31.5PB。平台汇聚8623万份居民健康档案，形成高质量医疗数据资源池， 为AI模型训练提供核心支撑。 建平台：建设数据开放、测试验证、成果转化平台，安全有序开放数据，助推创新药、智能医疗器械研发。 深融合：推动AI融入临床诊疗、中医药、基层卫生、公共卫生、医保服务等全链条。 促产业：以AI赋能生物医药、医疗器械、健康机器人等产业升级，培育个性化健康管理、智 ...

Core Insights - Beijing's health commission has released two key documents outlining plans for the development of AI applications in the healthcare sector from 2026 to 2027, aiming to establish a supportive AI industry framework by 2027 [1][2] - The core principle of the policies is "demand-driven, scenario-based," focusing on enhancing clinical diagnosis, grassroots health, and health management, while encouraging collaboration between medical institutions and quality AI companies [1][2] Group 1: Policy Objectives - The goal is to create an AI industry support system that facilitates precise demand matching, efficient data flow, rapid technology transfer, and collaborative ecosystem development [1] - The policies prioritize high-frequency and high-value medical scenarios, aiming to improve diagnostic efficiency and optimize healthcare resource supply [1][2] Group 2: Data Utilization and Security - The implementation of these policies relies on effective data utilization, with plans to integrate electronic medical records and imaging data from secondary and tertiary medical institutions into a comprehensive health information platform by the end of 2026 [2] - A governance system for the entire data lifecycle will be established to ensure data security and privacy, while also supporting AI model training and validation [2] Group 3: Industry Collaboration and Ethical Standards - The AI ecosystem in healthcare requires collaboration between medical enterprises, integrating computing power, models, data, applications, and scenarios to build a diversified industry ecosystem [2] - The policies emphasize ethical standards and patient safety, prohibiting the complete replacement of medical professionals' judgment by AI [2] Group 4: Support and Infrastructure - The health commission plans to seek multi-channel funding support and focus on infrastructure development, application promotion, and talent cultivation to ensure the successful implementation of the policies [2] - Specific initiatives include the establishment of dedicated computing clusters for healthcare and creating online platforms for precise supply-demand matching [2] Group 5: Practical Applications and Industry Response - Several medical institutions in Beijing have already begun to benefit from AI technologies, with successful implementations in areas such as AI-assisted diagnosis and imaging [3] - Companies are optimistic about leveraging high-quality health data from the health commission to enhance the precision and efficiency of stem cell research and development [3] - The introduction of these policies is a strategic move to leverage Beijing's advantages in the AI industry chain and rich medical resources, aligning with the national "Artificial Intelligence +" strategy [3]